Green Lifescience그린생명과학

Green Lifescience swung back to a small profit over the last twelve months after several loss-making years, but its shares are down 11.9% over one year.

Trailing twelve-month revenue to H1 2026 is about ₩58.6B with operating income of about ₩3.7B and net income of about ₩4.5B, against a much weaker 2025 when operating income was only about ₩0.2B. The company, which makes precision chemicals for pharmaceutical and materials customers, trades at a P/E of about 10 and P/B of about 1 on the data provided, with a market capitalisation of about ₩44.4B.

What stands out

• Revenue rose sharply in 2025 (up 62.3%) and trailing revenue to H1 2026 is about ₩58.6B, well above 2024's ₩24.9B.
• Operating margin is thin but positive on a trailing basis at 6.3%, compared with 0.5% in 2025 and losses in 2021 to 2023.
• Net income for the trailing period (about ₩4.5B) is higher than operating income, and the 2024 net profit was boosted relative to operating profit; the filings data does not explain the drivers of this gap.
• Balance sheet looks moderate: liabilities to equity of 32.3%, cash of about ₩14.2B against borrowings of ₩4.0B, and trailing free cash flow of about ₩3.1B.
• Recent filings include a half-year report, a major sales or supply contract (May 2026, later amended in June), a new facility investment, and a change of largest shareholder, while foreign ownership fell from 3.1% to 2.4% over the period.

What to watch

• The next quarterly or half-year results, to see whether operating margin holds above the 2025 level.
• Details of the new facility investment and the largest shareholder change, which the provided data does not describe in full.
• Foreign ownership and investor flows: foreign investors were net sellers over the last 20 days, and no news headlines were available in the data to explain recent moves.